Use of hR3 MAb and radiotherapy to treat patients with non small cells lung cancer (NSCLC) and brain metastasis.
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry.
- 03 Nov 2008 Preliminary results have been presented at the 2008 EORTC-NCI-AACR annual meeting, according to a YM Biosciences media release.
- 03 Nov 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History